[HTML][HTML] Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti… - … England Journal of …, 2013 - Mass Medical Soc
Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review
L Saba, C Gerosa, D Fanni, F Marongiu… - European Review for …, 2020 - iris.unica.it
OBJECTIVE: In human pathology, SARS-CoV-2 utilizes multiple molecular pathways to
determine structural and biochemical changes within the different organs and cell types. The …
determine structural and biochemical changes within the different organs and cell types. The …
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results …
U Platzbecker, G Avvisati, L Cicconi… - Journal of Clinical …, 2017 - ascopubs.org
Purpose The initial results of the APL0406 trial showed that the combination of all-trans-
retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …
retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …
Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study
AS Fassas, JR Passweg, A Anagnostopoulos… - Journal of …, 2002 - Springer
Abstract Rationale Phase I/II studies of autologous hematopoietic stem cell transplantation
(HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental …
(HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental …
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
ME Bernardo, E Piras, A Vacca… - Blood, The Journal …, 2012 - ashpublications.org
Sixty thalassemia patients (median age, 7 years; range, 1-37) underwent allogeneic
hematopoietic stem cell transplantation (HSCT) after a preparation combining thiotepa …
hematopoietic stem cell transplantation (HSCT) after a preparation combining thiotepa …
Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography …
Purpose To investigate the progression-free survival (PFS) of patients with advanced
Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive …
Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive …
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
R Saccardi, GL Mancardi, A Solari, A Bosi, P Bruzzi… - Blood, 2005 - ashpublications.org
Hematopoietic stem cell transplantation (HSCT) has been proposed for the treatment of
severe multiple sclerosis (MS). In a phase 2 multicenter study we selected 19 non–primary …
severe multiple sclerosis (MS). In a phase 2 multicenter study we selected 19 non–primary …
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
R Littera, C Carcassi, A Masala, P Piano, P Serra… - Aids, 2006 - journals.lww.com
Background: Hypersensitivity reaction to nevirapine, which in some cases can be fatal,
shows a higher prevalence in Sardinia in comparison with other Italian regions. Objective …
shows a higher prevalence in Sardinia in comparison with other Italian regions. Objective …
Unrelated bone marrow transplantation for β‐thalassemia patients: the experience of the Italian Bone Marrow Transplant Group
G La Nasa, F Argiolu, C Giardini… - Annals of the New …, 2005 - Wiley Online Library
Bone marrow transplantation (BMT) remains the only potentially curative treatment for
patients with thalassemia major. However, most candidates for BMT do not have a suitable …
patients with thalassemia major. However, most candidates for BMT do not have a suitable …
[HTML][HTML] Health related quality of life in Middle Eastern children with beta-thalassemia
G Caocci, F Efficace, F Ciotti, MG Roncarolo… - BMC blood …, 2012 - Springer
Background Thalassemia is a common disorder worldwide with a predominant incidence in
Mediterranean countries, North Africa, the Middle East, India, Central Asia, and Southeast …
Mediterranean countries, North Africa, the Middle East, India, Central Asia, and Southeast …